We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Partners to Establish Center for Medical Cannabis R&D in Israel

By LabMedica International staff writers
Posted on 20 Mar 2016
Two Israeli-based biotechnology firms have agreed to establish a center to concentrate research, development, and commercialization of medical marihuana and other cannabis products.

The partners are iCAN- Israel Cannabis (Beit Shemesh, Israel) and Breath of Life Pharma (BOL Pharma; Israel). More...
BOL Pharma, established in 2008, is regarded as Israel’s leading medical cannabis drug development firm, while iCAN- Israel Cannabis is actively engaged in identifying and accelerating cannabis technologies in Israel.

The primary objectives of the new center will be to strengthen research and development of new cannabis-related technologies with the goal of successful commercialization. The center will serve as an incubator for cannabis innovation as well as a validator of cannabis-based medicines and agricultural-technological and topical product development based on stringent guidelines and standards.

Dr. Tamir Gedo, CEO of BOL Pharma, said, “BOL greenhouses allow developers to use the professional services and knowledge of BOL Pharma, in order to produce strains, improve growing conditions, master extraction, formulation, and production of materials under GMP conditions, and ultimately to enable companies to commercialize their research and go to market. Together with iCAN- Israel Cannabis, we will incubate companies from all over the world to test and validate medical products for the global cannabis market.”

Saul Kaye, CEO of iCAN- Israel Cannabis, said “We are thrilled to partner with BOL Pharma and provide a global incubator and proving ground for cannabis technology. We are confident our partnership will enable the most promising start-ups and innovators in Israel and abroad, to create world class products for the global cannabis economy.”

Related Links:

iCAN- Israel Cannabis
Breath of Life Pharma 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Two major international studies identified noninvasive tests that can accurately diagnose and assess MASLD and MASH, reducing reliance on liver biopsy. (Image Credit: Adobe Stock)

Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read more

Molecular Diagnostics

view channel
Image:Graphical Abstract (Victori P, Hua K, Twigger AJ, et al. Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer. Cell Reports Medicine, 2026. doi:10.1016/j.xcrm.2026.103119.)

Digital Twins Predict Treatment Response in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive, fast-growing subtype that accounts for about 15% of all breast cancer cases. Its tumor cells lack estrogen receptors, progesterone receptors, and... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: Graphical Abstract (Andrew Medina-Marino, Chibuzor M Babalola, Mandisa M Mdingi, et al. Clinical Infectious Diseases, 2026. doi:10.1093/cid/ciag577.)

Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births

Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.